Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Company Financial Support Encourages Mammography Screening: J&J
December 26, 2005
- Stop the press!
December 26, 2005
- SURVEY 3 articles
December 26, 2005
- Discussions to Continue on Pricing of Long-listed Drugs, Frequency of Price Revisions
December 26, 2005
- R&D NEWS IN BRIEF
December 26, 2005
- JGPMA to Submit Petition on Full Specifications for Generics
December 26, 2005
- Outline of FY2006 NHI Pricing System Reform Approved
December 26, 2005
- 13 New Kit Products Listed
December 26, 2005
- New R&D Tax Break System to Unify 2 Existing Systems
December 26, 2005
- REGULATORY NEWS IN BRIEF -1-
December 26, 2005
- REGULATORY NEWS IN BRIEF -2-
December 26, 2005
- Blopress Retains No. 1 Ranking, Lipitor Takes No. 2 Spot
December 26, 2005
- Takeda Becomes Alfresa HD's Top Supplier
December 26, 2005
- BUSINESS NEWS IN BRIEF
December 26, 2005
- Requirements for DPC Hospitals Proposed by Korosho
December 19, 2005
- (Proposed) Direction for FY2006 NHI Pricing System Reform
December 19, 2005
- Pollinosis Much More Common in Boys Under 10 Years of Age
December 19, 2005
- Korosho's Reform Proposal Would Weaken Industry: Mr Crenshaw of PhRMA
December 19, 2005
- Airborne Cedar Pollen Levels Should Be Lower in 2006
December 19, 2005
- Long-listed Drugs' NHI Price Reductions to Negatively Affect State Finances: OPIR
December 19, 2005
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…